Annex 1
Monitoring Framework WHO European Region Tuberculosis Action Plan 2021–
2030
The WHO European Region TB action plan 2021-2030 is supported with a Monitoring
framework that enables a harmonized approach to monitor the progress towards Regional TB-
AP 2021-2030 targets at both the national and regional levels and actions taken to put the End
TB strategy into practice. Monitoring is not limited to tracking data on the TB surveillance
and implementation of activities, but also includes evaluating the effectiveness and impact of
interventions, consequently providing foundation for advocacy and policy development.
The current document follows the structure of the previous Monitoring framework of the
WHO European Region TB action plan 2016-2020, with the overall intention of keeping the
limited number of indicators and maintaining details on calculations of each of the indicators
used. Limiting the number of indicators is intended to avoid overburdening the framework
and stay focused on issues that directly affect decision-making and provide measures of
effectiveness.
The framework consists of 28 indicators that allow monitoring of performance of the areas of
interventions in the action plan. Ten were selected as core indicators for monitoring and
reporting to the WHO Regional Committee for Europe (those highlighted in the list with E
(European)). The list of indicators closely follows the structure of the action plan. Each area
of intervention is reflected in the framework by one or more indicators, assessed by the task
force to represent the most accurate measure of performance of the group of activities.
The Monitoring framework includes indicators that allow oversight of progress towards
achievement of regional targets:
1. Impact indicators that measure progress towards the three End TB Strategy and WHO
European Region targets;
2. Outcome indicators that monitor broader changes in TB control enhanced as a result of a
set of interventions;
3. Output indicators that monitor progress of specific interventions that measure policy
environment, commitment and capacity among Member States.
Indicator development was guided by principles which defined that the indicators should be:
• Broad enough to reflect all aspects of the ambitious action plan;
• Sufficiently specific to address critical markers of success; and
• Concise, so as not to overburden national programmes.
In addition, selection of indicators was harmonized with the End TB Strategy’s recommended
top 10 global indicators, highlighted in the list with G (Global) and focusing on indicators that
are collected regularly through the routine recording and reporting system. These indicators,
while regional in scope, are designed to serve as a guide to the development or adjustment of
comprehensive monitoring plans at country level.
Baseline value, desired target, assessment frequency, monitoring mechanism and data source
are defined for each indicator/group of indicators. The framework includes quantitative and
qualitative indicators: if quantitative, numerators and denominators are listed; if qualitative,
basic criteria of favorable assessment (Yes/No) are listed.
Baseline levels in most cases were defined using information provided by each country
through the WHO/European Centre for Disease Prevention and Control (ECDC) annual TB
data collection process. This is standardized to the WHO recommended recording and
reporting framework, has Region-wide coverage, is undertaken only once (therefore avoiding
duplication of effort by countries and partners) and ensures a user-friendly mechanism for
data collection. The absence of baseline information in a limited number of indicators from
the full list might be explained by the unavailability of these data and/or questionable
reliability of the information available.
To prioritize the area of intervention, indicators will be measured according to the following
layers: 18 high-priority countries to stop TB in the WHO European Region;1 European
Union/European Economic Area countries; and WHO European Region level. Analysis by
country will be performed to assess country-specific benchmarks, performance over time and
the eventual achievement of all objectives.
Most indicators will be monitored annually. In addition to the joint WHO/ECDC annual data
collection, desk reviews will be performed at the beginning of implementation of the action
plan and when full implementation is expected to monitor activities that are not reflected in
the WHO/ECDC TB data collection form. In-depth assessment of reports from countries and
external technical support will provide additional material to support the measurement of
indicators. In the absence of these main sources of information, an interview with the national
programme (or equivalent) will be undertaken to assess performance on interventions
implemented as part of the action plan. Only data approved by Member States will be used in
monitoring the action plan.
The indicators outlined in the regional Monitoring framework should be integrated with
national TB control programmes’ Monitoring and Evaluation (M&E) frameworks at country
level. In addition to the indicators outlined in the regional framework, countries may also
include additional indicators to monitor progress of national strategies, taking into account
country-specific priorities.
The full results of assessments of performance on interventions delivered through
implementation of the action plan will be presented every second year via a joint
WHO/ECDC report on TB surveillance and monitoring in Europe. The report will consist of
analysis and interpretation of data based on the indicators and will include recommendations.
Progress in action plan implementation will be reported every second year to the Regional
Committee and monitoring reports will be presented to the meeting of national TB
programme managers/country focal points that is open to stakeholders and civil society
organizations involved in TB control in the Region.
1
18 high-priority countries for TB control in the WHO European Region: Armenia, Azerbaijan, Belarus, Bulgaria,
Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Romania, Russian Federation,
Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan. Reference: Plan to Stop TB in 18 High-priority
Countries in the WHO European Region, 2007–2015 (ISBN 978 92 890 7180 2)
Saatja: EURO TB <
[email protected]>
Saadetud: 24.02.2020 18:48
Adressaat: Elen Ohov <
[email protected]>
Koopia: DARA, Masoud <
[email protected]>; YEDILBAYEV, Askar <
[email protected]>;
KUCHUKHIDZE, Giorgi <
[email protected]>; MULLABAYEV, Garif
<
[email protected]>; VYSHNEVSKA, Svitlana <
[email protected]>; Triin Uusberg
<
[email protected]>; SM Info <
[email protected]>; <
[email protected]>;
<
[email protected]>; REINAP, Marge <
[email protected]>; REINAP, Marge
<
[email protected]>
Teema: Draft Monitoring and Evaluation Framework to end tuberculosis in WHO European
Region 2021-2030
Manused: Estonia.pdf; List of ME indicators.pdf; Monitoring and evaluation framework
narative.pdf
Dear Ms. Ohov,
Enclosed is the letter from Dr Masoud Dara, Coordinator, Communicable Diseases Division of Health
Emergencies and Communicable Diseases, about the status of the Monitoring and Evaluation Framework
to end tuberculosis in WHO European Region 2021-2030 for your kind consideration.
Sincerely yours,
Joint Tuberculosis, HIV and Hepatitis Programme (JTH)
Division of Health Emergencies and Communicable Diseases (DEC)
World Health Organization, Regional Office for Europe (WHO/Europe)
UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark
Tel: +45 4533 6827 or +45 4533 6609 ¦ Fax: +45 4533 7001
E-mail:
[email protected];
Description of indicators, Tuberculosis action plan 2021-2030
Legend:
• Three indicators are highlighted bold (1.B.5, 1.C.4 and 1.C.6). They measure the targets set in the region.
• The 10 European core indicators are highlighted grey (including the 3 indicators above)
• In red are the corresponding 10 core indicators developed by WHO Headquarters (see also MAF-TB appendix).
1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION
A Systematic screening of contacts and high-risk groups
1.A.1 Coverage of contacts with systematic screening for Numerator: Number of contacts of TB patients identified in the reporting year who
active TB (G) were screened for TB*
Denominator 1: Number of contacts of active TB patients identified in the reporting
year
Denominator 2: Estimated number of household contacts of TB patients in the
reporting year **
*According to the national guidelines
**For measuring the coverage of the contact investigation; source: United Nations,
Department of Economic and Social Affairs, Population Division. Household Size and
Composition Around the World.
Global Top-10 indicator
(6) Contact investigation coverage
Number of contacts of people with bacteriologically confirmed TB who were
evaluated for TB, divided by the number eligible, expressed as a percentage.
B. Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests
1.B.1 Percentage of notified new and relapse TB patients Numerator: Number of new and relapse patients tested using a WHO-recommended
tested using WHO-recommended rapid tests (G) rapid diagnostic (for example Xpert MTB/RIF) as the initial diagnostic test (regardless of
test result)
Denominator: Total number of new and relapse patients notified
Global Top-10 indicator
(4) Percentage of new and relapse TB patients tested using a WHO recommended
rapid diagnostic (WRD) at the time of diagnosis
Number of new and relapse TB patients tested using a WRD at the time
of diagnosis, divided by the total number of new and relapse TB patients,
expressed as a percentage.
1.B.2 DST coverage (%) among all pulmonary TB patients (G) Numerator: Number of patients with drug susceptibility test results for at least
rifampicin among pulmonary TB patients*
Denominator 1: Total number of pulmonary TB patients notified
Denominator 2: Total number of bacteriologically confirmed pulmonary TB patients
* DST coverage includes results from molecular tests (e.g. WHO recommended rapid
diagnostic test) as well as conventional phenotypic DST results
Global Top-10 indicator
(7) Drug-susceptibility testing (DST) coverage for TB patients
Number of TB patients with DST results for at least rifampicin, divided by
the total number of notified (new and retreatment) cases in the same year,
expressed as a percentage. DST coverage includes results from molecular
(e.g. Xpert MTB/RIF) as well as conventional phenotypic DST results.
1.B.3 RR/MDR TB case detection rate (%) Numerator: Total number of bacteriologically confirmed pulmonary RR/MDR-TB
patients notified
Denominator: Total number of estimated RR/MDR-TB patients among notified
pulmonary TB
1.B.4 TB case detection rate (%) Numerator: Total number of new and relapse TB patients notified
Denominator: Total number of estimated new and relapse TB patients
1.B.5 TB notification rate per 100 000 population (E) Numerator: Total number of new and relapse TB patients notified
Denominator: Population number/100 000
1.B.6 RR-MDR/TB notification rate per 100 000 population Numerator: Total number of bacteriologically confirmed RR-TB or MDR-TB patients
notified
Denominator: Population number/100 000
Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient
C. support to facilitate treatment adherence
1.C.1 Percentage of patients starting first line TB treatment at Estimated percentage of patients that are receiving TB treatment at the ambulatory
the outpatient healthcare level (E) (outpatient) level (%) among patients starting first-line TB treatment
Additional indicator: Estimated percentage of patients that are receiving TB treatment
at the ambulatory (outpatient) level (%) among patients starting second-line TB
treatment
1.C.2 Percentage of notified RR/MDR TB patients enrolled in Numerator: Total number of RR/MDR TB patients enrolled into SLD treatment
treatment (G) (E) Denominator: Total number of RR/MDR TB patients notified
Global Top-10 indicator
(1) TB treatment coverage
Number of new and relapse cases that were notified and treated, divided by
the estimated number of incident TB cases in the same year, expressed as a
percentage.
1.C.3 Treatment success rate (%) among all new and relapse Numerator: New and relapse TB patients notified in a specified period who were
TB patients (G) successfully treated
Denominator: Total number of new and relapse TB patients notified in the same period
Global Top-10 indicator
(2) TB treatment success rate
Percentage of notified TB patients who were successfully treated. The target
is for drug-susceptible and drug-resistant TB combined, although outcomes
should also be reported separately.
1.C.4 Treatment success rate (%) among the RR/MDR-TB Numerator: Number of bacteriologically confirmed RR/MDR TB patients during the
treatment cohort (G) (E) specified period that were successfully treated
Denominator: Number of bacteriologically confirmed RR/MDR TB patients that started
on a prescribed TB treatment regimen during the specified period.
Global Top-10 indicator
(2) TB treatment success rate
Percentage of notified TB patients who were successfully treated. The target
is for drug-susceptible and drug-resistant TB combined, although outcomes
should also be reported separately.
1.C.5 Treatment success rate (%) among the XDR-TB Numerator: Number of bacteriologically confirmed XDR-TB patients during the
treatment cohort (G) (E) specified period that were successfully treated
Denominator: Number of bacteriologically confirmed XDR-TB patients that started on a
prescribed TB treatment regimen during the specified period.
Global Top-10 indicator
(2) TB treatment success rate
Percentage of notified TB patients who were successfully treated. The target
is for drug-susceptible and drug-resistant TB combined, although outcomes
should also be reported separately.
1.C.6 TB mortality rate per 100 000 population (G) (E) Numerator: Estimated number of TB deaths (ICD A15-19; B90) (from VRS)
Denominator: Total number of population/100 000
Global Top-10 indicator
(10) Case fatality ratio (CFR)
Number of TB deaths divided by estimated number of incident cases in the
same years, expressed as a percentage.
D. Collaborative tuberculosis/HIV activities, and management of relevant comorbidities
1.D.1 TB/HIV case-detection rate (%) Numerator: Total number of notified HIV co-infected TB patients among new and
relapse TB patients in a specified period
Denominator: Total number of estimated TB/HIV co-infected patients among new and
relapse TB patients
1.D.2 HIV testing coverage (%) (G) (E) Numerator: Total number of notified new and relapse TB patients in a specified period
with reported HIV status
Denominator: Total number of notified new and relapse TB patients in the specified
period
Global Top-10 indicator
(9) Documentation of HIV status among TB patients
Number of new and relapse TB patients with documented HIV status, divided
by the number of new and relapse TB patients notified in the same year,
expressed as a percentage.
1.D.3 Percentage of HIV positives among new and relapse TB Numerator: Total number of notified new and relapse TB patients in a specified period
patients with documented test results who are HIV positive
Denominator: Total number of notified new and relapse TB patients in the specified
period with documented HIV test results
1.D.4 ART coverage (%) among TB/HIV patients Numerator: Total number of notified new and relapse TB/HIV patients in a specified
period who are enrolled in antiretroviral therapy (ART)*
Denominator: Total number of notified new and relapse TB patients in the specified
period who are HIV positive
* Within 8 weeks of starting TB treatment
E. Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis
1.E.1 LTBI treatment enrolment rate (%) among PLHIV (G) Numerator: Total number of new HIV patients enrolled in LTBI treatment in a specified
period
Denominator: Total number of new HIV patients eligible for LTBI treatment in the
specified period
Global Top-10 indicator
(5) Latent TB infection (LTBI) treatment coverage
Number of people living with HIV newly enrolled in HIV care and the number
of children aged <5 years who are household contacts of cases started on
LTBI treatment, divided by the number eligible for treatment, expressed as a
percentage (separately for each of the two groups).
1.E.2 LTBI treatment coverage (%) in childhood TB contacts Numerator: Total number of child TB contacts age <5 years enrolled in LTBI treatment
aged under 5 years (G) (E) in the specified period
Denominator: Estimated number of child TB contacts eligible for LTBI treatment in the
specified period
Global Top-10 indicator
(5) Latent TB infection (LTBI) treatment coverage
Number of people living with HIV newly enrolled in HIV care and the number
of children aged <5 years who are household contacts of cases started on
LTBI treatment, divided by the number eligible for treatment, expressed as a
percentage (separately for each of the two groups).
2. BOLD POLICIES AND SUPPORTIVE SYSTEMS
A. Political commitment with adequate resources, including universal health coverage policy
2.A.1 Number of Members States that have a TB control Method of measurement: review (53 Member States, this includes the example of TB
strategy document publicly available that includes control measures integrated in overall strategy or standalone document)
targets for reduction in TB mortality and incidence in
line with the regional and global targets set in the
resolution WHA67.1 and EUR/RC70/RX (E)
B. Health systems strengthening in all functions, including well-aligned financing mechanisms for tuberculosis and human resources
2.B.1 Percentage of TB-affected households that experience Source: TB catastrophic cost surveys
catastrophic costs due to TB (G) (E)
Global Top-10 indicator
(3) Percentage of TB-affected households that experience catastrophic costs
due to TB
Number of people treated for TB (and their households) who incur
catastrophic costs (direct and indirect combined), divided by the total number
of people treated for TB.
C. Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilence
2.C.1 Treatment coverage with modified Shorter all-oral Numerator: Number of TB patients treated with modified Shorter all-oral Treatment
Treatment Regimens (mSTR) (G) Regimens (mSTR)
Denominator: Number of notified patients eligible for treatment with modified Shorter
all-oral Treatment Regimens (mSTR)
Global Top-10 indicator
(8) Treatment coverage, new TB drugs
Number of TB patients treated with regimens that include new (endorsed
after 2010) TB drugs, divided by the number of notified patients eligible for
treatment with new TB drugs, expressed as a percentage.
E. Community systems and civil society engagement
2.E.1 Number of Member States with adopted standards and Number of Member States with adopted standards and operational procedures for civil
operational procedures for civil society organizations society organizations (CSOs) in the provision of psycho-social support services to ensure
(CSOs) in the provision of psycho-social support services treatment adherence for people with TB
to ensure treatment adherence for people with TB
2.E.2 Number of Member States with adopted procedures of Number of Member States with adopted procedures of subcontracting mechanisms
subcontracting mechanisms under the state funds or under the state funds or other relevant funding mechanisms for CSOs in the provision of
other relevant funding mechanisms for CSOs in the psycho-social support and active case-finding services for people with TB
provision of psycho-social support and active case-
finding services for people with TB
2.E.3 Proportion of people with TB found through active case- Numerator: Number of people with TB from key affected population referred by
finding activities implemented through CSOs community volunteers/NGOs for TB diagnosis and treatment
Denominator: Total number of people with TB notified during the same period
2.E.4 Proportion of people with TB who started TB treatment Numerator: number of people with TB who started TB treatment and who received any
and who received any form of treatment adherence form of treatment adherence support from CSO (including psycho-social support)
support from CSO (including psycho-social support) Denominator: Total number of people with TB started treatment during the same
period
F. Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons
2.F.1 Treatment success rate (%) of new and relapse TB Numerator: New and relapse TB patients notified in a specified period that were
patients among prisoners successfully treated in prisons
Denominator: Total number of new and relapse TB patients notified in the same period
in prisons
3. INTENSIFIED RESEARCH AND INNOVATION
A. Discovery, development and rapid uptake of new tools, interventions and strategies
3.A.1 Number of Member States with a standing alone
national TB research agenda or research priorities
integrated in the national TB strategic plans or relevant
policies.
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 24 February 2020
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Ms. Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜROFÜREUROPA
Adviser
ЕВРОПЕЙСКОЕРЕГИОНАЛЬНОЕБЮРО European Union Affairs and International Co-
Head office:
operation Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected] Tallinn 10122
Website: http://www.euro.who.int Estonia
Our reference: Yourreference:
Notre référence: Votre référence:
UnserZeichen: IhrZeichen:
См. нашномер: НаВашномер:
Draft Monitoring and Evaluation Framework to end tuberculosis in WHO European Region
2021-2030
Dear Ms. Ohov,
In 2015, the 65th WHO Regional Committee for Europe endorsed the Tuberculosis Action Plan 2016-
2020, in line with the Global End TB Strategy. In a follow up to the resolution EUR/RC65/17, the final
report of implementation of the Action Plan is to be submitted to 70th Regional Committee in
September 2020. The secretariat is finalizing the mentioned report which will be submitted for Member
States’ review and endorsement along with a suggestion to extend the validity of Tuberculosis Action
Plan with a vision to end TB epidemic, with zero affected families facing catastrophic costs due to TB
by 2030. To monitor the progress and in line with the commitments articulated in the UN High Level
Political Declaration, a Monitoring and Evaluation Framework 2021-2030 with new indicators and
targets are prepared. These indicators, while regional in scope, are designed to serve as a guide to the
development or adjustment of comprehensive monitoring plans at country level.
The process of development of this framework, included several meetings and consultations of WHO
Regional Office for Europe with experts working in the monitoring and evaluation field:
- On 28-30 August 2019, the WHO Regional Office for Europe organized a meeting of the WHO
consultants involved in the TB surveillance and response monitoring related activities in the
Region. As an output of this meeting, an initial draft of the new framework with description of
indicators was developed.
- As a next step, in October 2019, the WHO Regional Office for Europe established a Task Force,
representing different partners from international, governmental and non-governmental
organizations, including national tuberculosis programmes, people affected and civil society
organizations working in the field of Tuberculosis to finalize Monitoring and Evaluation
framework of the TB Action Plan for the WHO European Region.
- The Task Force held regular online meetings followed by several rounds of revisions of the list
and description of indicators. Monitoring and Evaluation framework was finalized in January
2020.
UN City,Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
The Monitoring and Evaluation framework consists of 28 indicators that allow monitoring of
performance of the areas of interventions in the Action Plan. Ten were selected as core indicators for
monitoring and reporting to the WHO Regional Committee for Europe. The list of indicators closely
follows the structure of the action plan. Each area of intervention is reflected in the framework by one
or more indicators, assessed by the task force to represent the most accurate measure of performance
of the group of activities.
We have the pleasure to share with you the mentioned draft Monitoring and Evaluation framework
for review by your national experts by 28 February 2020. Your experts may contact Dr Giorgi
Kuchukhidze (
[email protected]) should they have any questions or need any clarification.
Yours sincerely,
Dr Masoud Dara
Coordinator, Communicable Diseases
Division of Health Emergencies and Communicable Diseases
WHO Regional Office for Europe
Copy for information to:
Ms Triin Uusberg
Head
European and International Coordination Department
Ministry of Social Affairs
Suur-Ameerika 1
Tallinn 10129, Estonia
H.E. Ms Katrin Saarsalu-Layachi
Ambassador Extraordinary and Plenipotentiary, Permanent Representative
Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations
in Geneva
Chemin du Petit-Saconnex 28A
Genève CH-1209, Switzerland
H.E. Mr Märt Volmer
Ambassador Extraordinary and Plenipotentiary
Embassy of the Republic of Estonia
Frederiksgade 19, 4th floor
Copenhagen K 1265, Denmark
Ms Marge Reinap
Head of WHO Office
WHO Country Office, Estonia
Paldiski Road 81
Tallinn 10617, Estonia
–2–